CryoCor begins AF (atrial fibrillation) cryotherapy trial:
This article was originally published in Clinica
Executive Summary
The US FDA has given CryoCor the go-ahead to begin a feasibility study of its minimally invasive cardiac cryoablation system for treating atrial fibrillation (AF). The study will involve around 30 patients at up to five centres and will assess the San Diego, California firm's system, called CryoCor, as a treatment for paroxysmal, or intermittent, AF. Patient follow-up of the trial is scheduled for completion by the fourth quarter of 2002, after which CryoCor plans to file for FDA approval to begin a pivotal US trial to support a marketing application for the device. The device has yet to be CE-marked for sale in Europe.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.